Skip to main content
Year archive

Pharming Group N.V. — 2025 filings

All 60 regulatory filings released by Pharming Group N.V. (PHARM) in 2025, sourced directly from the official regulator.

60 Filings
2025 Period
2025 filings (60)
Filing Released Lang
6-K
Foreign Filer Report
2025-11-06 English
Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow
Interim / Quarterly Report Q3 2025
2025-11-06 Dutch
Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow
Interim / Quarterly Report Q3 2025
2025-11-06 English
6-K
Foreign Filer Report
2025-10-22 English
Pharming Group provides update on previously announced G&A expense reduction plan
Earnings Release Q4 2025
2025-10-07 Dutch
Pharming Group provides update on previously announced G&A expense reduction plan
Regulatory Filings
2025-10-07 English
6-K
Foreign Filer Report
2025-10-06 English
6-K
Foreign Filer Report
2025-10-01 English
Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years
Regulatory Filings
2025-10-01 Dutch
Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years
Regulatory Filings
2025-10-01 English
6-K
Foreign Filer Report
2025-09-10 English
6-K
Foreign Filer Report
2025-09-02 English
6-K
Foreign Filer Report
2025-07-31 English
Pharming Group reports second quarter and first half 2025 financial results and provides business update
Interim / Quarterly Report H1 2025
2025-07-31 Dutch
Pharming Group reports second quarter and first half 2025 financial results and provides business update
Interim / Quarterly Report H1 2025
2025-07-31 English
Pharming Group N.V., Halfjaarlijkse financiële verslaggeving
Interim / Quarterly Report H1 2025
2025-07-31 English
6-K
Foreign Filer Report
2025-06-24 English
Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis
Earnings Release FY 2024
2025-06-24 Dutch
Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis
Regulatory Filings
2025-06-24 English
Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders
AGM Information
2025-06-12 Dutch
Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders
AGM Information
2025-06-12 English
6-K
Foreign Filer Report
2025-06-11 English
6-K
Foreign Filer Report
2025-05-08 English
Pharming Group reports first quarter 2025 financial results and provides business update
Interim / Quarterly Report Q1 2025
2025-05-08 Dutch
Pharming Group reports first quarter 2025 financial results and provides business update
Interim / Quarterly Report Q1 2025
2025-05-08 English
Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director
AGM Information
2025-05-01 Dutch
Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director
Report Publication Announcement
2025-05-01 English
Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director
AGM Information
2025-05-01 English
6-K
Foreign Filer Report
2025-04-30 English
6-K
Foreign Filer Report
2025-04-25 English
6-K
Foreign Filer Report
2025-04-23 English
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS
Regulatory Filings
2025-04-23 Dutch
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS
Regulatory Filings
2025-04-23 English
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS
Regulatory Filings
2025-04-23 English
6-K
Foreign Filer Report
2025-04-03 English
20-F
Annual Report FY 2024
2025-04-03 English
Pharming Group announces the filing of its 2024 Annual Report and Form 20-F
Report Publication Announcement
2025-04-03 Dutch
Pharming Group announces the filing of its 2024 Annual Report and Form 20-F
Report Publication Announcement
2025-04-03 English
Pharming Group N.V., Jaarlijkse financiële verslaggeving
Annual Report (ESEF) FY 2024
2025-04-03 English
6-K
Foreign Filer Report
2025-03-20 English
Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation
Regulatory Filings
2025-03-20 Dutch
Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation
Regulatory Filings
2025-03-20 English
6-K
Foreign Filer Report
2025-03-13 English
Pharming Group reports fourth quarter and full year 2024 financial results and provides business update
Earnings Release FY 2024
2025-03-13 Dutch
Pharming Group reports fourth quarter and full year 2024 financial results and provides business update
Earnings Release Q4 2024
2025-03-13 English
Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders
AGM Information
2025-03-04 Dutch
Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders
Board/Management Information
2025-03-04 English
6-K
Foreign Filer Report
2025-03-04 English
Pharming Technologies B.V. vergroot haar belang in Abliva AB (publ) naar 92,70 procent
M&A Activity
2025-02-21 Dutch
Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent
M&A Activity
2025-02-21 English
6-K
Foreign Filer Report
2025-02-20 English
Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period
M&A Activity
2025-02-10 Dutch
Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period
Delisting Announcement
2025-02-10 English
6-K
Foreign Filer Report
2025-02-07 English
6-K
Foreign Filer Report
2025-01-21 English
Pharming Group to convene Extraordinary General Meeting of Shareholders
Regulatory Filings
2025-01-21 Dutch
Pharming Group to convene Extraordinary General Meeting of Shareholders
AGM Information
2025-01-21 English
6-K
Foreign Filer Report
2025-01-21 English
Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer
Board/Management Information
2025-01-21 Dutch
Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer
Board/Management Information
2025-01-21 English